AJMC® in the Press, January 24, 2025

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach to now include the full spectrum of inflammatory bowel disease.

On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.

A meta-analysis found a low risk of HIV transmission in people taking antiretroviral therapy (ART) in high-income countries.

Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.

This year in review of 2024 milestones in non–small cell lung cancer (NSCLC) features coverage of the LAURA trial presented in June at the American Society of Clinical Oncology meeting in Chicago, Illinois, and the EMPOWER-Lung 1 and the Beamion LUNG-1 studies presented in September at the World Conference on Lung Cancer in San Diego, California. It includes updated data from Beamion LUNG-1 shared at the European Society for Medical Oncology (ESMO) Asia meeting held in Singapore in December, as well as an interview with Edgardo Santos Castillero, MD, FACP, on the significance of the Beamion LUNG-1 results. This phase 1a/b dose escalation study examined zongertinib in patients with HER2 mutation-positive NSCLC.

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for enhanced strategies to optimize postrecurrence treatment.